Our Stories

Our Stories

트위터 링크드

28/02/2022 Samsung Bioepis Celebrates its 10th Anniversary – a letter from our CEO
This year, Samsung Bioepis celebrates its 10 years in business.

When we established our company in 2012, we believed there was an opportunity in the market for biosimilars to become a viable solution to lower healthcare costs while expand access to treatment. Although there were only a handful of companies in the industry, we had faith in our colleagues’ drive and grit, let alone our faith in science.

We embarked on our very first project with limited resources and little experience of developing biosimilars. We set our timer to countdown to December 2014, a goal date to file for the first product approval to the European Medicines Agency. It was a very tight deadline and an ambitious goal. And we got our first approval in January 2016 ‒ the “first” etanercept biosimilar ever approved and launched in Europe. In the span of next five years, we added five additional products to our portfolio, including the latest product which became the “first” ophthalmology biosimilar approved by the European Commission and the U.S. Food and Drug Administration. Our biosimilars are now treating patients across 39 countries around the world, helping to drive down costs while expanding access to treatment. Three of our six approved products have helped nearly 250,000 patients in Europe alone, contributing over € 2.6 billion of healthcare savings in 2021. i

We are now a team of over 900 colleagues, headquartered in Incheon, Korea, with a strong global presence. Without our dedicated colleagues, we would not be the company that we are today. Their perseverance and commitment to our vision and values have allowed us to create a unique culture and best-in class team dedicated to delivering outstanding results.

One thing that has remained unchanged in the past 10 years is our company values. Every meeting and decision we make is driven by a data-driven mindset, transparency, integrity, partnership, responsiveness, and a supportive culture. With a strong belief in our core values, and as we continue our journey towards improving the lives of patients ‒ not only patients who could not afford or access effective treatment, but also patients without viable treatment ‒ I am very optimistic that our next decade will be filled with innovations, improvements, and more great people. Our work has just begun.

With sincere gratitude and appreciation,
Christopher Hansung Ko, President and Chief Executive Officer, Samsung Bioepis

i. Biogen’s Q4 & Full Year 2021 Financial Results and Business Update. Available at: https://investors.biogen.com/static-files/019bc8a4-527e-4565-a58b-91ef680630c1

확인 취소
레이어 팝업 닫기